Arizona State Retirement System raised its stake in Regenxbio Inc (NASDAQ:RGNX) by 9.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,618 shares of the biotechnology company’s stock after purchasing an additional 3,618 shares during the quarter. Arizona State Retirement System owned 0.13% of Regenxbio worth $3,218,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of the company. Public Employees Retirement Association of Colorado bought a new position in shares of Regenxbio in the third quarter worth $256,000. Russell Investments Group Ltd. boosted its holdings in shares of Regenxbio by 2,489.5% in the third quarter. Russell Investments Group Ltd. now owns 56,892 shares of the biotechnology company’s stock worth $4,295,000 after acquiring an additional 54,695 shares during the period. Alps Advisors Inc. bought a new position in shares of Regenxbio in the third quarter worth $504,000. Botty Investors LLC boosted its holdings in shares of Regenxbio by 9.0% in the third quarter. Botty Investors LLC now owns 224,187 shares of the biotechnology company’s stock worth $16,926,000 after acquiring an additional 18,473 shares during the period. Finally, Texas Permanent School Fund boosted its holdings in shares of Regenxbio by 10.1% in the third quarter. Texas Permanent School Fund now owns 18,485 shares of the biotechnology company’s stock worth $1,396,000 after acquiring an additional 1,696 shares during the period. 81.17% of the stock is owned by hedge funds and other institutional investors.
RGNX has been the subject of a number of analyst reports. TheStreet raised Regenxbio from a “d+” rating to a “c” rating in a report on Monday, September 17th. Bank of America lowered Regenxbio from a “buy” rating to a “neutral” rating and raised their price target for the stock from $64.00 to $80.00 in a report on Monday, July 23rd. Barclays raised their price target on Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Raymond James raised their price target on Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, September 7th. Finally, Chardan Capital raised their price target on Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 16th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $84.07.
In related news, CFO Vittal Vasista sold 73,418 shares of Regenxbio stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $70.20, for a total transaction of $5,153,943.60. Following the completion of the sale, the chief financial officer now owns 147,242 shares of the company’s stock, valued at $10,336,388.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Patrick J. Christmas sold 5,000 shares of Regenxbio stock in a transaction on Monday, August 20th. The shares were sold at an average price of $65.96, for a total value of $329,800.00. Following the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at approximately $1,495,247.24. The disclosure for this sale can be found here. Insiders have sold 286,585 shares of company stock valued at $18,814,681 in the last three months. 16.90% of the stock is owned by corporate insiders.
NASDAQ:RGNX opened at $66.37 on Friday. The firm has a market cap of $2.25 billion, a P/E ratio of -27.09, a price-to-earnings-growth ratio of 13.98 and a beta of -0.49. Regenxbio Inc has a 52-week low of $23.25 and a 52-week high of $85.10.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.30. The company had revenue of $5.31 million during the quarter. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. On average, equities analysts expect that Regenxbio Inc will post 1.64 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Arizona State Retirement System Has $3.22 Million Stake in Regenxbio Inc (RGNX)” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/11/10/arizona-state-retirement-system-has-3-22-million-stake-in-regenxbio-inc-rgnx.html.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More: Earnings Per Share (EPS)
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.